Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 5/20 | 0.51 |
| ▸ | TBK1 | Q9UHD2 | 4/20 | 0.47 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 3/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.40 |
| ▸ | PLK4 | O00444 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20242759 | 0.79 | SYK (0.43) | SYKTBK1EGFRERBB2JAK2 | |
| SCHEMBL14024429 | 0.77 | SYK (0.53) | SYKEGFRJAK2PLK4 | |
| SCHEMBL4883637 | 0.77 | PDE4A (0.49) | EGFR | |
| SCHEMBL14024582 | 0.76 | KDR (0.56) | SYKTBK1PLK4 | |
| SCHEMBL20242735 | 0.73 | EGFR (0.41) | SYKTBK1GRM4EGFR | |
| SCHEMBL3459344 | 0.72 | SRC (0.59) | SYKEGFR | |
| SCHEMBL29877093 | 0.72 | CYP3A4 (0.48) | SYKMAPK1GRM5 | |
| SCHEMBL2627279 | 0.71 | CYP3A4 (0.46) | SYK | |
| SCHEMBL30098499 | 0.71 | CYP3A4 (0.46) | SYK | |
| SCHEMBL2284267 | 0.71 | EGFR (0.72) | SYKGRM4EGFRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349859-B2 | Pyrimidine derivatives | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-01-08 | — | — | US | disclosed |
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | HUTCHISON MEDIPHARMA ENTERPRISES LIMETED (BS) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | CCND2, KDR, FLT4 | SYK 2248/4885TBK1 2166/4885IKBKE 2932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.